clinical trial · NCT04804553
Apremilast Pediatric Study in Children With Active Juvenile Psoriatic Arthritis
Active Juvenile Psoriatic ArthritisApremilastPlacebo
brief summary
The study will aim to estimate the efficacy of apremilast compared with placebo in the treatment of juvenile psoriatic arthritis (JPsA) in pediatric participants 5 to less than 18 years of age.
started
Mar 17, 2022
primary completion
Mar 21, 2028
completion
Dec 29, 2028
last updated
Jul 24, 2026
official title
A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Apremilast in Children From 5 to Less Than 18 Years of Age With Active Juvenile Psoriatic Arthritis (PEAPOD)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol